Flebogamma DIF

Flebogamma DIF

human normal immunoglobulin




Grifols Asia Pacific
Concise Prescribing Info
Human normal Ig
Replacement therapy in primary immunodeficiency syndromes eg, congenital agammaglobulinaemia & hypogammaglobulinaemia, common variable immunodeficiency, severe combined immunodeficiency, Wiskott Aldrich syndrome; myeloma or chronic lymphocytic leukaemia w/ severe secondary hypogammaglobulinaemia & recurrent infections; childn w/ congenital AIDS & recurrent infections. Idiopathic thrombocytopenic purpura (ITP), in childn or adults at high risk of bleeding or prior to surgery to correct the platelet count; Guillain-Barre syndrome; Kawasaki disease. Allogeneic bone marrow transplantation.
Dosage/Direction for Use
Replacement therapy in primary immunodeficiency syndrome Starting dose: 0.4-0.8 g/kg; thereafter 0.2-0.8 g/kg every 2-4 wk to obtain IgG trough level of at least 4-6 g/L. Replacement therapy in myeloma or chronic lymphocytic leukaemia w/ severe hypogammaglobulinaemia & recurrent infections; replacement therapy in childn w/ AIDS & recurrent infection 0.2-0.4 g/kg every 3-4 wk. ITP 0.8-1 g/kg on day 1, may be repeated once w/in 3 days, or 0.4 g/kg/day for 2-5 days. Guillain-Barre syndrome 0.4 g/kg/day for 3-7 days. Kawasaki disease 1.6-2 g/kg in divided doses for 2-5 days or 2 g/kg as a single dose in combination w/ acetylsalicylic acid. Allogeneic bone marrow transplantation 0.5 g/kg wkly starting 7 days before & up to 3 mth after transplantation in the treatment of infections & prophylaxis of graft versus host disease, & 0.5 g/kg mthly until Ab levels return to normal in cases of persistent lack of Ab production.
Hypersensitivity to homologous Ig especially in IgA deficiency due to antibodies against IgA (very rare). Fructose intolerance.
Special Precautions
High rate of infusion; patients w/ hypo- or agammaglobulinaemia w/ or w/o IgA deficiency, receiving human normal Ig therapy for the 1st time, or when human normal Ig is switched or during a long interval since the previous infusion (rare). Obese patients; preexisting risk for thrombotic events. Discontinue use in case of renal impairment. Maintain adequate hydration prior to initiation; monitor urine output & serum creatinine levels; avoid concomitant use w/ loop diuretics. Perform appropriate tests for the presence of antineutrophil Ab if transfusion-related acute lung injury (TRALI) is suspected. May interfere w/ serological test for red cell Ab eg, Coombs' test. May affect ability to drive or operate machinery. Pregnancy & lactation.
Adverse Reactions
Drug Interactions
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J06BA02 - immunoglobulins, normal human, for intravascular adm. ; Belongs to the class of normal human immunoglobulins. Used in passive immunizations.
Flebogamma DIF soln for infusion 5%
10 mL x 1's;100 mL x 1's;200 mL x 1's;400 mL x 1's;50 mL x 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in